These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immunohistochemical study of p53, c-erbB-2 and nm23 proteins in human gastric cancer].
    Author: Wei Z, Wu Y, Zhai Z.
    Journal: Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):378-81. PubMed ID: 10920922.
    Abstract:
    OBJECTIVE: To evaluate p53, c-erbB-2 and nm23 oncoproteins in diagnosis of gastric cancer. METHODS: The expression of p53, c-erbB-2 and nm23 oncoproteins was detected immunohistochemically in 141 surgically resected specimens and 93 endoscopic biopsy specimens of gastric cancer. RESULTS: The positive rate of p53, c-erbB-2 and nm23 immunoreactivity was 45.8-56.3%, 18.3-31.2% and 72.9%-81.3% respectively. No immunoreactivity was observed in the tumor-adjacent normal mucosa and non-tumor biopsy specimens. The presence of c-erbB-2 was correlated with the size of tumor, grade of tumor differentiation and Lanren classification. Patients with c-erbB-2 positive tumor had lower 5-year survival rate. The expression of nm23 was negatively correlated with the depth of invasion, and lymphnode metastasis. The positive rates of p53, c-erbB-2 and nm23 had no statistical difference between biopsy and resected specimens. CONCLUSION: Determination of p53, c-erbB-2 and nm23 oncoproteins immunohistochemically might be useful in the diagnosis and differential diagnosis, clinical staging, and predicting prognosis of gastric cancer.
    [Abstract] [Full Text] [Related] [New Search]